<DOC>
	<DOCNO>NCT01392235</DOCNO>
	<brief_summary>RATIONALE : Famitinib tyrosin-inhibitor agent target c-Kit , VEGFR2 , PDGFR , VEGFR3 , Flt1 Flt3 . Phase I study show drug 's toxicity manageable . PURPOSE : This phase II trial study well famitinib work treat patient recurrent and/or metastatic NPC .</brief_summary>
	<brief_title>Famitinib Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma ( NPC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Histologically cytologic confirm recurrent and/or metastatic nasopharyngeal carcinoma ( NPC ) Have fail ≥2 line chemotherapy At least one measurable lesion , large 10 mm diameter spiral CT scan ( scan layer ≤ 5 mm ) ≥ 18 ≤ 70 year age ECOG performance scale 02 Life expectancy 3 month More 4 week operation , chemotherapy , radiotherapy , cytotoxic agent tyrosine kinase inhibitor Adequate hepatic , renal , heart , hematologic function ( hemoglobin ≥ 90g/L , platelet ≥ 80×10^9/L , neutrophil ≥ 1.5×10^9/L , 24hour urinary protein ≤ 1.0 g total bilirubin &lt; 1.25×the upper limit normal ( ULN ) , serum transaminase &lt; 1.5×the ULN ( If liver metastasis , serum transaminase &lt; 2.5×the ULN ) , serum creatine ≤ 1x ULN , creatinine clearance rate ＞ 50ml/min , Cholesterol≤7.75 mmol/L triglyceride≤2.5 x ULN , LVEF : ≥ 50 % Patients could provide 46 piece organization wax pathological section Female : All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 6 month last dose test article . Child bear potential , negative urine serum pregnancy test result initiate Famitinib . Male : All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 6 month last dose test article . Signed date informed consent . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . Prior therapy tyrosine kinase inhibitor agent target VEGFR , PDGFR cKit Prior radiotherapy 2 course Before time , second malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Less 4 week last clinical trial Any factor influence usage oral administration Known Spinal Cord compression disease brain pia mater CT /MRI screen Imageology show tumor lesion le 5 mm great vessel Preexisting uncontrolled hypertension define 140/90 mmHg despite use single medical therapy , cla s I ( NCI CTCAE 3.0 ) myocardial ischemia , arrhythmia , cardiac insufficiency URT : urine protein ≥ ++ ＞ 1.0 g 24 h Longterm untreated wound fracture Blood coagulation abnormal , hemorrhagic tendency ( eg . active peptic ulcer disease ) receive therapy thrombolysis anticoagulation . Within 6 month first treatment occurrs artery / venous thromboembolic event , cerebral vascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism , etc . Application anticoagulant vitamin K antagonist warfarin , heparin analogue ; If prothrombin time international normalize ratio ( INR ) ≤ 1.5 , purpose prevention , use small dos warfarin ( 1mg orally , daily ) lowdose aspirin ( 80mg 100mg daily ) allow Preexisting thyroid dysfunction , even use medical therapy , thyroid function maintain normal range Abuse Psychiatric drug dysphrenia Viral hepatitis type B type C Immunodeficiency : HIV positive , acquire immunodeficiency , congenital immunodeficiency , organ transplantation Evidence significant medical illness investigator 's judgment substantially increase risk associate subject 's participation completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Recurrent and/or Metastatic Nasopharyngeal Carcinoma ( NPC )</keyword>
</DOC>